ИНСТИТУСИО КАТАЛАНА ДЕ РЕСЕРКА И ЭСТУДИС АВАНКАТС (ES);ЛАБОРАТОРЬОС ДЕЛЬ ДР. ЭСТЕВЕ; С.А. (ES);ФУНДАСИО ПРИВАДА ИНСТИТУТ ДЕ РЕСЕРКА ДЕ ЛЯ СИДА-КАЙКСА (ES);ЛАБОРАТОРЬОС ДЕЛЬ ДР. ЭСТЕВЕ, С.А. (ES);РУПРЕХТ-КАРЛС-УНИВЕРЗИТЕТ ХАЙДЕЛЬБЕРГ (DE)
1. The use of an inhibitor of the interaction between sialoadhesin and sialyllactose for the treatment or prevention of a disease associated with an infection caused by an enveloped virus. The use according to claim 1, wherein said inhibitor is selected from the group consisting of sialyllactose, a molecule containing a sialyllactose molecule, an anti-sialoadhesin antibody and a sialyllactose binding molecule, or a vesicle containing a molecule containing a sialyllactose molecule. The use according to claim 2, wherein the molecule containing the sialyllactose molecule is a ganglioside having less than four sialic acids. The use according to any one of paragraphs. 1-3, where at least some of the lipids in the envelope of said enveloped virus contain sialyllactose. The use according to any one of paragraphs. 1-3, where the enveloped virus is selected from the group consisting of a retrovirus, preferably HIV, and a virus from the family of filoviruses. 6. The use of claim 5, wherein HIV is HIV-1.7. The use of claim 4, wherein the disease associated with the HIV infection is AIDS. A composition for treating or preventing a disease associated with an enveloped virus infection comprising an antigen-loaded antigen-presenting cell and an inhibitor of the interaction between sialoadhesin and sialyllactose. 9. The composition of claim 8, wherein said inhibitor is selected from the group consisting of sialyllactose, a molecule containing a sialyllactose molecule, an anti-sialoadhesin antibody, and a sialyllactose binding molecule. The composition of claim 9, wherein the molecule containing the sialyllactose molecule is a ganglioside having less than four sialic acids. The composition according to any one of paragraphs. 8-10 where the antigen1. Применение ингибитора взаимодействия между сиалоадгезином и сиалиллактозой для лечения или предупреждения заболевания, связанного с инфекцией, вызванной имеющим оболочку вирусом.2. Применение по п. 1, где указанный ингибитор выбран из гр
